These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10976550)

  • 1. Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype.
    Herrlin K; Massele AY; Rimoy G; Alm C; Rais M; Ericsson O; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 2000 Aug; 68(2):189-98. PubMed ID: 10976550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
    Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
    Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
    Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians.
    Skjelbo E; Mutabingwa TK; Bygbjerg Ib; Nielsen KK; Gram LF; Brøosen K
    Clin Pharmacol Ther; 1996 Mar; 59(3):304-11. PubMed ID: 8653993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.
    Hoskins JM; Shenfield GM; Gross AS
    Eur J Clin Pharmacol; 2003 Nov; 59(8-9):611-4. PubMed ID: 13680037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
    Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
    Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.
    Hoskins JM; Shenfield GM; Gross AS
    Br J Clin Pharmacol; 1998 Nov; 46(5):499-504. PubMed ID: 9833604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide.
    Jeppesen U; Rasmussen BB; Brøsen K
    Clin Pharmacol Ther; 1997 Sep; 62(3):279-86. PubMed ID: 9333103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans.
    Funck-Brentano C; Bosco O; Jacqz-Aigrain E; Keundjian A; Jaillon P
    Clin Pharmacol Ther; 1992 May; 51(5):507-12. PubMed ID: 1587064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
    Kaneko A; Bergqvist Y; Taleo G; Kobayakawa T; Ishizaki T; Björkman A
    Pharmacogenetics; 1999 Jun; 9(3):317-26. PubMed ID: 10471063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans.
    Partovian C; Jacqz-Aigrain E; Keundjian A; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1995 Sep; 58(3):257-63. PubMed ID: 7554698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.
    Funck-Brentano C; Becquemont L; Lenevu A; Roux A; Jaillon P; Beaune P
    J Pharmacol Exp Ther; 1997 Feb; 280(2):730-8. PubMed ID: 9023285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.
    Rasmussen BB; Nielsen TL; Brøsen K
    Eur J Clin Pharmacol; 1998; 54(9-10):735-40. PubMed ID: 9923577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype.
    Marinac JS; Balian JD; Foxworth JW; Willsie SK; Daus JC; Owen R; Flockhart DA
    Clin Pharmacol Ther; 1996 Aug; 60(2):138-44. PubMed ID: 8823231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker.
    Kim MJ; Bertino JS; Gaedigk A; Zhang Y; Sellers EM; Nafziger AN
    Clin Pharmacol Ther; 2002 Aug; 72(2):192-9. PubMed ID: 12189366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between CYP2C19 genotype and proguanil oxidative polymorphism.
    Coller JK; Somogyi AA; Bochner F
    Br J Clin Pharmacol; 1997 Jun; 43(6):659-60. PubMed ID: 9205829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.
    Roh HK; Dahl ML; Tybring G; Yamada H; Cha YN; Bertilsson L
    Pharmacogenetics; 1996 Dec; 6(6):547-51. PubMed ID: 9014204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.
    Wang JH; Liu ZQ; Wang W; Chen XP; Shu Y; He N; Zhou HH
    Clin Pharmacol Ther; 2001 Jul; 70(1):42-7. PubMed ID: 11452243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.